Cargando…
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin are well-known therapeutic targets for renal cell carcinoma (RCC). Sunitinib is an agent that targets VEGF receptors and is considered to be a standard treatment for metastatic or unresectable clear cell RCC (ccRCC). However...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482605/ https://www.ncbi.nlm.nih.gov/pubmed/26114873 http://dx.doi.org/10.1371/journal.pone.0130980 |